"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets

scientific article published on August 2014

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1039/C4MB00147H
P698PubMed publication ID24841339
P5875ResearchGate publication ID262537909

P50authorXinyong LiuQ75661546
P2093author name stringPeng Zhan
Dongwei Kang
Yu'ning Song
Wenmin Chen
P2860cites workDesign of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groupsQ24611024
Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolonesQ24798680
Fragment screening and HIV therapeuticsQ26826945
Novel therapeutic strategies targeting HIV integraseQ27003960
HIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel SiteQ27640888
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlaysQ27653562
Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse TranscriptaseQ27657535
RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural informationQ27657612
Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranesQ27658013
Structure of HIV-1 Reverse Transcriptase with the Inhibitor β-Thujaplicinol Bound at the RNase H Active SiteQ27658584
Crystal structure of HIV-1 reverse transcriptase bound to a non-nucleoside inhibitor with a novel mechanism of actionQ27659605
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding siteQ27660224
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replicationQ27661671
Structural Basis for the Inhibition of RNase H Activity of HIV-1 Reverse Transcriptase by RNase H Active Site-Directed InhibitorsQ27661750
Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1Q27663609
Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1Q27666603
Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding PocketQ27667348
Structural and Binding Analysis of Pyrimidinol Carboxylic Acid and N-Hydroxy Quinazolinedione HIV-1 RNase H InhibitorsQ27667421
Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease HQ27667836
Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based designQ27667923
Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment ScreeningQ27675974
Structural and Inhibition Studies of the RNase H Function of Xenotropic Murine Leukemia Virus-Related Virus Reverse TranscriptaseQ27676777
Small Molecule Regulation of Protein Conformation by Binding in the Flap of HIV ProteaseQ27677124
Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturationQ27677515
Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase InhibitorsQ27678141
New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of ActionQ27678745
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided HybridizationQ27684133
Structure-Based Design of 2-Aminopyridine Oxazolidinones as Potent and Selective Tankyrase InhibitorsQ27684184
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitorsQ27684686
Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptaseQ39613869
5-Modified-2'-dU and 2'-dC as mutagenic anti HIV-1 proliferation agents: synthesis and activity.Q39746338
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidateQ39800337
Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptaseQ39889724
KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesisQ40423448
HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Q41879018
Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategyQ42537068
Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptaseQ42549637
Nucleotide competing reverse transcriptase inhibitors: discovery of a series of non-basic benzofurano[3,2-d]pyrimidin-2-one derived inhibitorsQ42712159
Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitorsQ42712397
Discovery of small molecule HIV-1 integrase dimerization inhibitorsQ42719255
Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffoldQ42876787
Pyrazole NNRTIs 3: optimisation of physicochemical propertiesQ43283624
Pyrazole NNRTIs 1: design and initial optimisation of a novel templateQ43285390
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acidQ44248249
A novel mechanism for inhibition of HIV-1 reverse transcriptaseQ44365269
Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimidesQ44829634
6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitroQ44897779
Development of an AlphaScreen-based HIV-1 integrase dimerization assay for discovery of novel allosteric inhibitorsQ45157847
Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesisQ45177265
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactorQ45586245
Complexes of HIV-1 integrase with HAT proteins: multiscale models, dynamics, and hypotheses on allosteric sites of inhibition.Q46010779
Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integraseQ46346735
D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75.Q46437340
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistanceQ46504568
A multidisciplinary approach for the identification of novel HIV-1 non-nucleoside reverse transcriptase inhibitors: S-DABOCs and DAVPsQ46849623
Identification of HIV-1 reverse transcriptase dual inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach.Q53348127
Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase.Q54564921
Lethal mutagenesis of HIV.Q36008905
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitorsQ36276790
Structural basis of the allosteric inhibitor interaction on the HIV-1 reverse transcriptase RNase H domain.Q36300994
Allosteric inhibition of HIV-1 integrase activityQ36920004
Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptasesQ36928605
Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.Q36928993
Recent advances in the research of HIV-1 RNase H inhibitorsQ37294454
Exploiting drug-resistant enzymes as tools to identify thienopyrimidinone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.Q37432679
Designed multiple ligands: an emerging anti-HIV drug discovery paradigmQ37515905
Molecular basis of human immunodeficiency virus drug resistance: an update.Q37555266
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 updateQ37581700
Design strategies of novel NNRTIs to overcome drug resistanceQ37595588
Kinetic target-guided synthesisQ37716658
Cosalane and its analogues: a unique class of anti-HIV agentsQ37764371
Targeting protein-protein interactions: a promising avenue of anti-HIV drug discoveryQ37780233
HIV-1 RT-Associated RNase H Function Inhibitors: Recent Advances in Drug DevelopmentQ37790713
Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010).Q37860335
HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug designQ37869442
Recent developments of peptidomimetic HIV-1 protease inhibitorsQ37921839
Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.Q38081000
Rationally designed multitarget anti-HIV agentsQ38081542
Click chemistry for drug development and diverse chemical-biology applications.Q38093289
Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 updateQ38155891
"Old friends in new guise": exploiting privileged structures for scaffold re-evolution/refiningQ38180459
Aptamer displacement identifies alternative small-molecule target sites that escape viral resistanceQ38299698
Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.Q38339368
The pharmacology of HIV drug resistanceQ39133627
Design of cell-permeable stapled peptides as HIV-1 integrase inhibitorsQ39140673
Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interactionQ39187770
Discovery of novel inhibitors of LEDGF/p75-IN protein-protein interactionsQ39212927
Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerizationQ39337204
Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activityQ39346109
4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration processQ39504985
Alkyl hydroxybenzoic acid derivatives that inhibit HIV-1 protease dimerization.Q39555479
Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H functionQ39583211
Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteinsQ27687498
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateQ28250395
Lethal mutagenesis of HIV with mutagenic nucleoside analogsQ28369649
Ligand efficiency: a useful metric for lead selectionQ29617403
Structure of HIV-1 reverse transcriptase bound to an inhibitor active against mutant reverse transcriptases resistant to other nonnucleoside inhibitors.Q30342229
LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivityQ30399011
Rapid Diversity‐Oriented Synthesis in Microtiter Plates for In Situ Screening of HIV Protease InhibitorsQ31024145
High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylationsQ33218516
Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamideQ33308195
Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activityQ33373484
Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75.Q33476232
An allosteric mechanism for inhibiting HIV-1 integrase with a small moleculeQ33488152
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reactionQ33635875
HIV-1 reverse transcriptase and antiviral drug resistance. Part 1.Q33900441
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Q33900459
Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.Q33907525
Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studiesQ33945786
Combining biophysical screening and X-ray crystallography for fragment-based drug discoveryQ33991624
From nonpeptide toward noncarbon protease inhibitors: metallacarboranes as specific and potent inhibitors of HIV proteaseQ34081415
Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase.Q34122562
Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug DevelopmentQ34226132
Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication.Q34350400
Recent progress in the research of small molecule HIV-1 RNase H inhibitorsQ34398645
Discovery of inhibitors to block interactions of HIV-1 integrase with human LEDGF/p75 via structure-based virtual screening and bioassays.Q34436597
Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.Q34439041
Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor seriesQ34643481
Rationally designed dual inhibitors of HIV reverse transcriptase and integraseQ34645420
6-Benzoyl-3-hydroxypyrimidine-2,4-diones as dual inhibitors of HIV reverse transcriptase and integraseQ34762297
3-Hydroxypyrimidine-2,4-diones as an inhibitor scaffold of HIV integraseQ34770674
Discovery of a small-molecule HIV-1 integrase inhibitor-binding siteQ34772524
N-3 Hydroxylation of Pyrimidine-2,4-diones Yields Dual Inhibitors of HIV Reverse Transcriptase and IntegraseQ34779869
5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1.Q35000909
Allosteric inhibitor development targeting HIV-1 integraseQ35046515
Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of actionQ35185934
P433issue8
P407language of work or nameEnglishQ1860
P304page(s)1998-2022
P577publication date2014-08-01
P1433published inMolecular BioSystemsQ3319467
P1476title"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets
P478volume10

Reverse relations

cites work (P2860)
Q26777448Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors
Q47612838Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H.
Q38843215Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach
Q36164152First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach
Q38587368Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities
Q40106207Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1.
Q88641336Mebendazole exhibits potent anti-leukemia activity on acute myeloid leukemia
Q38662691Medicinal chemistry insights in the discovery of novel LSD1 inhibitors
Q38260066Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).
Q40618808Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182.
Q58760446Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase
Q41534943Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections

Search more.